Helicobacter pylori infection and gastric cancer
Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-med...
Gespeichert in:
Veröffentlicht in: | Baillière's best practice & research. Clinical gastroenterology 2007-01, Vol.21 (2), p.281-297 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 297 |
---|---|
container_issue | 2 |
container_start_page | 281 |
container_title | Baillière's best practice & research. Clinical gastroenterology |
container_volume | 21 |
creator | Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin) |
description | Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades. |
doi_str_mv | 10.1016/j.bpg.2007.02.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70310435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691807000133</els_id><sourcerecordid>2807408491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</originalsourceid><addsrcrecordid>eNp9kUFr2zAYhsVYWbK2P2CXYRj0Zvf7JFu2GAxK6JpBoYduZyHLn4oyx84kp5B_X7kJFHrYSTo874v0vIx9QSgQUF5vinb3VHCAugBeAPAPbImV4DkqlB_nO8dcKmwW7HOMG4AUUuoTW2AtGs7reslgTb23Y2vsRCHbHfox-MwPjuzkxyEzQ5c9mTgFbzNrBkvhgp0500e6PJ3n7M_P29-rdX7_cPdrdXOf21KUU16hMcogSXQKSEnXNFJ2HEsojXIgW1tVkhx3wkpw2DUNJsAp59oGFQhxzq6Ovbsw_ttTnPTWR0t9bwYa91HXIBBKUSXw2ztwM-7DkN6mEQUojhJ4ovBI2TDGGMjpXfBbEw4aQc8y9UYnmXqWqYFreM18PTXv2y11b4mTvQR8PwKURDx7CjpaT8lS50MSqLvR_7f-x7u07f3gren_0oHi2y90TAH9OK85jwn1PKQQ4gWdv5cK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1130921602</pqid></control><display><type>article</type><title>Helicobacter pylori infection and gastric cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) ; El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creator><creatorcontrib>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) ; El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creatorcontrib><description>Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1016/j.bpg.2007.02.002</identifier><identifier>PMID: 17382277</identifier><identifier>CODEN: BPRCB6</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adenocarcinoma - epidemiology ; Adenocarcinoma - etiology ; Adenocarcinoma - prevention & control ; Animals ; Antibiotics ; Cancer ; chronic gastritis ; Confidence intervals ; cytokines ; Disease prevention ; Disease Progression ; Epidemiology ; gastric cancer ; Gastritis - epidemiology ; Gastritis - physiopathology ; Gastroenterology and Hepatology ; Helicobacter Infections - epidemiology ; Helicobacter Infections - etiology ; Helicobacter Infections - physiopathology ; Helicobacter Infections - therapy ; Helicobacter pylori ; Helicobacter pylori - pathogenicity ; host genetic factors ; Humans ; Infections ; Lymphoma, B-Cell, Marginal Zone - epidemiology ; Lymphoma, B-Cell, Marginal Zone - etiology ; Lymphoma, B-Cell, Marginal Zone - physiopathology ; MALT lymphoma ; Meta-analysis ; Pathogenesis ; Polymorphism, Genetic ; polymorphisms ; Risk Factors ; Stomach Neoplasms - microbiology ; Stomach Neoplasms - prevention & control ; Studies ; Therapy ; Ulcers ; Virulence</subject><ispartof>Baillière's best practice & research. Clinical gastroenterology, 2007-01, Vol.21 (2), p.281-297</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</citedby><cites>FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bpg.2007.02.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17382277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</creatorcontrib><creatorcontrib>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creatorcontrib><title>Helicobacter pylori infection and gastric cancer</title><title>Baillière's best practice & research. Clinical gastroenterology</title><addtitle>Best Pract Res Clin Gastroenterol</addtitle><description>Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.</description><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - etiology</subject><subject>Adenocarcinoma - prevention & control</subject><subject>Animals</subject><subject>Antibiotics</subject><subject>Cancer</subject><subject>chronic gastritis</subject><subject>Confidence intervals</subject><subject>cytokines</subject><subject>Disease prevention</subject><subject>Disease Progression</subject><subject>Epidemiology</subject><subject>gastric cancer</subject><subject>Gastritis - epidemiology</subject><subject>Gastritis - physiopathology</subject><subject>Gastroenterology and Hepatology</subject><subject>Helicobacter Infections - epidemiology</subject><subject>Helicobacter Infections - etiology</subject><subject>Helicobacter Infections - physiopathology</subject><subject>Helicobacter Infections - therapy</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - pathogenicity</subject><subject>host genetic factors</subject><subject>Humans</subject><subject>Infections</subject><subject>Lymphoma, B-Cell, Marginal Zone - epidemiology</subject><subject>Lymphoma, B-Cell, Marginal Zone - etiology</subject><subject>Lymphoma, B-Cell, Marginal Zone - physiopathology</subject><subject>MALT lymphoma</subject><subject>Meta-analysis</subject><subject>Pathogenesis</subject><subject>Polymorphism, Genetic</subject><subject>polymorphisms</subject><subject>Risk Factors</subject><subject>Stomach Neoplasms - microbiology</subject><subject>Stomach Neoplasms - prevention & control</subject><subject>Studies</subject><subject>Therapy</subject><subject>Ulcers</subject><subject>Virulence</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFr2zAYhsVYWbK2P2CXYRj0Zvf7JFu2GAxK6JpBoYduZyHLn4oyx84kp5B_X7kJFHrYSTo874v0vIx9QSgQUF5vinb3VHCAugBeAPAPbImV4DkqlB_nO8dcKmwW7HOMG4AUUuoTW2AtGs7reslgTb23Y2vsRCHbHfox-MwPjuzkxyEzQ5c9mTgFbzNrBkvhgp0500e6PJ3n7M_P29-rdX7_cPdrdXOf21KUU16hMcogSXQKSEnXNFJ2HEsojXIgW1tVkhx3wkpw2DUNJsAp59oGFQhxzq6Ovbsw_ttTnPTWR0t9bwYa91HXIBBKUSXw2ztwM-7DkN6mEQUojhJ4ovBI2TDGGMjpXfBbEw4aQc8y9UYnmXqWqYFreM18PTXv2y11b4mTvQR8PwKURDx7CjpaT8lS50MSqLvR_7f-x7u07f3gren_0oHi2y90TAH9OK85jwn1PKQQ4gWdv5cK</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</creator><creator>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Helicobacter pylori infection and gastric cancer</title><author>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) ; El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - etiology</topic><topic>Adenocarcinoma - prevention & control</topic><topic>Animals</topic><topic>Antibiotics</topic><topic>Cancer</topic><topic>chronic gastritis</topic><topic>Confidence intervals</topic><topic>cytokines</topic><topic>Disease prevention</topic><topic>Disease Progression</topic><topic>Epidemiology</topic><topic>gastric cancer</topic><topic>Gastritis - epidemiology</topic><topic>Gastritis - physiopathology</topic><topic>Gastroenterology and Hepatology</topic><topic>Helicobacter Infections - epidemiology</topic><topic>Helicobacter Infections - etiology</topic><topic>Helicobacter Infections - physiopathology</topic><topic>Helicobacter Infections - therapy</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - pathogenicity</topic><topic>host genetic factors</topic><topic>Humans</topic><topic>Infections</topic><topic>Lymphoma, B-Cell, Marginal Zone - epidemiology</topic><topic>Lymphoma, B-Cell, Marginal Zone - etiology</topic><topic>Lymphoma, B-Cell, Marginal Zone - physiopathology</topic><topic>MALT lymphoma</topic><topic>Meta-analysis</topic><topic>Pathogenesis</topic><topic>Polymorphism, Genetic</topic><topic>polymorphisms</topic><topic>Risk Factors</topic><topic>Stomach Neoplasms - microbiology</topic><topic>Stomach Neoplasms - prevention & control</topic><topic>Studies</topic><topic>Therapy</topic><topic>Ulcers</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</creatorcontrib><creatorcontrib>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</au><au>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Helicobacter pylori infection and gastric cancer</atitle><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle><addtitle>Best Pract Res Clin Gastroenterol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>21</volume><issue>2</issue><spage>281</spage><epage>297</epage><pages>281-297</pages><issn>1521-6918</issn><eissn>1532-1916</eissn><coden>BPRCB6</coden><abstract>Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>17382277</pmid><doi>10.1016/j.bpg.2007.02.002</doi><tpages>17</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1521-6918 |
ispartof | Baillière's best practice & research. Clinical gastroenterology, 2007-01, Vol.21 (2), p.281-297 |
issn | 1521-6918 1532-1916 |
language | eng |
recordid | cdi_proquest_miscellaneous_70310435 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adenocarcinoma - epidemiology Adenocarcinoma - etiology Adenocarcinoma - prevention & control Animals Antibiotics Cancer chronic gastritis Confidence intervals cytokines Disease prevention Disease Progression Epidemiology gastric cancer Gastritis - epidemiology Gastritis - physiopathology Gastroenterology and Hepatology Helicobacter Infections - epidemiology Helicobacter Infections - etiology Helicobacter Infections - physiopathology Helicobacter Infections - therapy Helicobacter pylori Helicobacter pylori - pathogenicity host genetic factors Humans Infections Lymphoma, B-Cell, Marginal Zone - epidemiology Lymphoma, B-Cell, Marginal Zone - etiology Lymphoma, B-Cell, Marginal Zone - physiopathology MALT lymphoma Meta-analysis Pathogenesis Polymorphism, Genetic polymorphisms Risk Factors Stomach Neoplasms - microbiology Stomach Neoplasms - prevention & control Studies Therapy Ulcers Virulence |
title | Helicobacter pylori infection and gastric cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Helicobacter%20pylori%20infection%20and%20gastric%20cancer&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=Lochhead,%20Paul,%20BSc%20(Hons),%20MB%20CHB,%20MRCP%20(UK)&rft.date=2007-01-01&rft.volume=21&rft.issue=2&rft.spage=281&rft.epage=297&rft.pages=281-297&rft.issn=1521-6918&rft.eissn=1532-1916&rft.coden=BPRCB6&rft_id=info:doi/10.1016/j.bpg.2007.02.002&rft_dat=%3Cproquest_cross%3E2807408491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1130921602&rft_id=info:pmid/17382277&rft_els_id=S1521691807000133&rfr_iscdi=true |